While ICON's earnings forecast dipped slightly, the consensus price target remains unchanged. Despite the slower expected revenue growth, ICON is still predicted to outperform the wider industry growth.
Upgrades •$マルケタ(MQ.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $15 •$ノースウェスト・ナチュラル・ホールディング(NWN.US)$: BofA Securities Upgrades to Neutral from Underperform - PT $53 (from $51) •$オーチス・ワールドワイド(OTIS.US)$: Barclays Upgrades to Overweight from Equalweight - PT $82 (from $80) •$スノーフレーク(SNOW.US)$: Rosenblatt Upgrades to Buy from Neutral - PT $255 (from $325) Downgrades •$イートン(ETN.US)$: Barclays Downgrades to Underweight from Eq...
$ブリストル・マイヤーズ スクイブ(BMY.US)$$武田薬品工業(TAK.US)$$PPD Inc(PPD.US)$$アイコン(ICLR.US)$Anyone have any input on some of these Biotech and Research stocks below. Some of them are trading at pretty high prices. Yet a few of them are priced low and was wondering if now would be a good time to get in and hold for a long time. Thank you for any input or discussion. Bristol-Myers Squibb Company (BMY) Takeda Pharmaceutical Company (TAK) PPD Inc (PPD) ICON Public Limited Company (ICLR) Charles Rivers Laboratories International (CRL) Laboratory Corporation of America (LH) IDEXX Laboratories Inc (IDXX) Bio-Rad Laboratories Inc (BIO)
アイコンに関するコメント
TOP WATCH AH + 7/27 ⚡️
コラムTop upgrades and downgrades on 5/24
• $マルケタ(MQ.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $15
• $ノースウェスト・ナチュラル・ホールディング(NWN.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $53 (from $51)
• $オーチス・ワールドワイド(OTIS.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $82 (from $80)
• $スノーフレーク(SNOW.US)$ : Rosenblatt Upgrades to Buy from Neutral - PT $255 (from $325)
Downgrades
• $イートン(ETN.US)$ : Barclays Downgrades to Underweight from Eq...
コラムTop upgrades and downgrades on 4/12
• $アプティブ・PLC(APTV.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $112 (from $108)
• $ASM INTERNATIONAL NV SPON ADR EACH REP 1 ORD SHS(ASMIY.US)$ : Barclays Upgrades to Overweight from EqualWeight - PT $425 (from $300)
• $ブライトハウス ファイナンシャル(BHF.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $54 (from $53)
• $カーディナルヘルス(CAH.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $74 (from $54)
• $クラウドストライク(CRWD.US)$ : Goldman...
Biotech and Research Stocks
Bristol-Myers Squibb Company (BMY)
Takeda Pharmaceutical Company (TAK)
PPD Inc (PPD)
ICON Public Limited Company (ICLR)
Charles Rivers Laboratories International (CRL)
Laboratory Corporation of America (LH)
IDEXX Laboratories Inc (IDXX)
Bio-Rad Laboratories Inc (BIO)
good Q2 report
まだコメントはありません